Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345069 · ClinicalTrials.gov registry record
Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS)
A clinical trial of Premature Infant, sponsored by Children's Hospital Medical Center, Cincinnati.
- Active
- Registry status
- 393
- Enrollment target
- 1
- Study location
NCT03345069: Active study of Premature Infant, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT03345069 is a study of Premature Infant that is active but no longer recruiting, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 393 participants, above the 246-participant average among 9 other Premature Infant trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03345069, a study of Premature Infant, is active but no longer recruiting, sponsored by Children's Hospital Medical Center, Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- 393 participants
- Enrollment target
- 1
- Study location
Study Summary
The Early Prediction Study is a longitudinal population-based cohort study for very preterm infants ≤32 weeks gestational age. Preterm infants recruited from three greater Cincinnati and two Dayton area neonatal intensive care units (NICUs) will undergo advanced MRIs at 41 weeks postmenstrual age and neurodevelopmental testing at the corrected ages of two and three years correct age. The goal of the Early Prediction Study is to accurately predict motor, cognitive, and behavioral deficits in individual very preterm infants using neuroimaging technologies and established epidemiologic approaches.
Primary Outcome
Standardized assessment and diagnosis of cerebral palsy at 2 years corrected age
Conditions Studied
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2016-09-16 |
| Est. Completion | 2027-11 |
What the registry record for NCT03345069 still lists
NCT03345069 is an observational study that tracks outcomes without assigning an intervention. The registered 393 participants enrollment target is mid-sized for trials with a published cap, above the 246-participant average among 9 other Premature Infant trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Premature Infant appearing as the primary indexed condition, and to 0 interventions.
NCT03345069 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03345069 about?
NCT03345069 is a clinical study titled "Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS)". The Early Prediction Study is a longitudinal population-based cohort study for very preterm infants ≤32 weeks gestational age. Preterm infants recruited from three greater Cincinnati and two Dayton area neonatal intensive care units (NICUs) will undergo advanced MRIs at 41 weeks postmenstrual age an...
What is the current status of trial NCT03345069?
This trial is currently active not recruiting. The enrollment target is 393 participants. The study started on 2016-09-16. Estimated completion is 2027-11.
What conditions does trial NCT03345069 study?
This clinical trial studies the following conditions: Premature Infant.
Who is sponsoring clinical trial NCT03345069?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03345069 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Infant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03345069's enrollment target sits among peer trials
393 2nd of 9 the highest of 9 other Premature Infant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Premature Infant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
RECRUITING
-
Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial)
RECRUITING · NA
-
Growing Little PEAPODS Study
RECRUITING
-
Cycled Phototherapy
ACTIVE NOT RECRUITING · NA
-
Ultrasound Assessment of BC in the NICU
ACTIVE NOT RECRUITING
-
Work of Breathing and Kangaroo Mother Care
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- NCT06613698 · 393 participants · Phase 2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI